Real-world Study for the Safety of Albumin-Bound Paclitaxel in Malignant Tumors

CSPC Pharmaceutical Group

Status: Completed

Conditions: Cancer

Treatments: Other: Observational study

Study type: Observational

Funder types: Industry

Identifiers

NCT04060290

CSPC-KAL-AE-01

Details and patient eligibility

About

This is a multi-center, Prospective, observational study，to evaluate the safety and influencing factors of albumin-bound paclitaxel in the real-world chinese population，and evaluate of the efficacy of albumin-bound paclitaxel in patients with malignant tumors and its impact on quality of life.

Enrollment: 1,000 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• In patients with malignant tumor who have been treated with albumin-bound paclitaxel for the treatment.

Exclusion criteria

• No